Lifecore biomedical regains compliance with nasdaq listing requirements

Chaska, minn., sept. 12, 2024 (globe newswire) -- lifecore biomedical, inc. (nasdaq: lfcr ) (“lifecore” or the “company”), a fully integrated contract development and manufacturing organization (“cdmo”), today announced that it has received written notice from the nasdaq listing qualifications department stating that the company has regained compliance with the filing requirement in nasdaq listing rule 5250(c), which requires listed companies to timely file all required periodic financial reports with the securities and exchange commission, and that the company has also cured the deficiency under nasdaq listing rule 5620(a), which requires listed companies to hold an annual meeting of stockholders during each fiscal year. with the company in compliance with nasdaq listing rule 5250(c), and having cured its deficiency under nasdaq listing rule 5620(a), nasdaq has ceased any action to delist the company's common stock.
LFCR Ratings Summary
LFCR Quant Ranking